Skip to main content

Table 5 Absorbed dose delivered by each daughter* for selected tissues

From: Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

  Absorbed Dose (mGy/1 MBq 225/7Ac Administered); RBEnot applied
225Ac 221Fr 217At 213Bi 213Po 209Pb 209Tl 227Ac 227Th 223Ra 219Rn 215Po 211Pb 211Bi 207Tl 211Po
Red marrow 1.61E+02 1.71E+02 1.88E+02 1.23E+00 2.09E+01 4.50E−01 3.22E−02 1.87E−04 5.06E−03 3.38E−04 3.99E−04 4.37E−04 3.51E−05 3.86E−04 3.76E−05 1.21E−06
Spleen 1.10E+02 1.20E+02 1.34E+02 7.67E−01 1.13E+01 2.66E−01 2.43E−02 1.10E−04 6.19E−03 1.05E−05 1.20E−05 1.29E−05 1.01E−06 1.16E−05 9.00E−07 3.59E−08
Endosteal bone surface 7.41E+01 7.89E+01 8.61E+01 5.56E−01 9.30E+00 1.85E−01 1.47E−02 7.77E−05 5.63E−03 2.81E−03 3.24E−03 3.34E−03 6.05E−05 3.18E−03 5.84E−05 9.24E−06
Liver 1.53E+01 1.66E+01 1.86E+01 3.88E−01 5.39E+00 1.29E−01 1.51E−02 1.53E−05 6.50E−04 7.86E−06 8.91E−06 9.53E−06 8.64E−07 8.61E−06 7.46E−07 2.66E−08
Lungs 1.13E+00 1.24E+00 1.36E+00 7.45E−02 7.88E−01 2.03E−02 5.32E−03 8.35E−07 6.10E−05 1.92E−05 2.22E−05 2.40E−05 2.17E−06 2.15E−05 2.13E−06 6.67E−08
Kidneys 4.64E−01 5.14E−01 5.48E−01 1.44E−02 3.34E−06 3.59E−04 3.92E−03 3.37E−07 5.64E−04 8.11E−06 9.09E−06 9.67E−06 8.81E−07 8.78E−06 6.97E−07 2.70E−08
Pancreas 3.46E−01 3.85E−01 4.06E−01 2.89E−02 2.35E−01 5.69E−03 4.32E−03 2.46E−07 2.13E−05 6.13E−06 6.78E−06 7.16E−06 6.83E−07 6.54E−06 4.89E−07 2.00E−08
Adrenals 3.33E−01 3.80E−01 3.80E−01 4.63E−02 2.20E−01 6.86E−03 7.50E−03 2.56E−07 2.33E−05 6.04E−06 6.47E−06 6.70E−06 1.11E−06 6.23E−06 8.51E−07 1.87E−08
Heart wall 2.89E−01 3.22E−01 3.36E−01 2.77E−02 1.95E−01 5.19E−03 3.96E−03 2.18E−07 1.78E−05 5.08E−06 5.62E−06 5.93E−06 6.41E−07 5.42E−06 4.92E−07 1.66E−08
Thyroid 2.57E−01 2.87E−01 3.02E−01 1.88E−02 1.75E−01 4.06E−03 2.68E−03 1.83E−07 1.56E−05 4.81E−06 5.14E−06 5.32E−06 6.59E−07 4.95E−06 4.07E−07 1.49E−08
Ovaries 1.45E−01 1.66E−01 1.66E−01 1.37E−02 9.59E−02 2.25E−03 2.46E−03 1.03E−07 2.35E−04 3.00E−06 2.96E−06 2.92E−06 6.22E−07 2.82E−06 3.77E−07 8.21E−09
Thymus 1.04E−01 1.22E−01 1.10E−01 2.49E−02 6.35E−02 2.97E−03 4.09E−03 1.12E−07 8.70E−06 2.21E−06 2.06E−06 1.93E−06 1.15E−06 1.95E−06 9.85E−07 5.48E−09
Uterus 9.85E−02 1.15E−01 1.10E−01 1.14E−02 6.35E−02 1.53E−03 2.28E−03 7.00E−08 9.24E−06 2.16E−06 2.03E−06 1.93E−06 5.15E−07 1.93E−06 2.77E−07 5.47E−09
Breast 9.43E−02 1.07E−01 1.10E−01 9.37E−03 6.35E−02 1.51E−03 1.79E−03 6.85E−08 6.10E−06 1.72E−06 1.87E−06 1.93E−06 2.56E−07 1.79E−06 1.62E−07 5.41E−09
Brain 7.58E−02 8.61E−02 8.71E−02 9.24E−03 5.05E−02 1.51E−03 1.41E−03 5.68E−08 5.96E−06 2.29E−06 1.86E−06 1.54E−06 1.76E−06 1.73E−06 1.51E−06 4.43E−09
Muscle 5.22E−02 6.08E−02 5.74E−02 9.60E−03 3.32E−02 1.27E−03 1.61E−03 4.26E−08 4.48E−06 1.33E−06 1.15E−06 1.01E−06 9.87E−07 1.08E−06 8.74E−07 2.89E−09
Salivary glands 5.12E−03 1.06E−02 8.96E−05 5.67E−03 1.36E−06 1.13E−04 1.61E−03 4.54E−09 2.44E−06 9.21E−07 3.92E−07 1.19E−09 1.34E−06 3.21E−07 1.09E−06 1.47E−10
Eye lens 2.34E−03 5.22E−03 4.54E−05 2.56E−03 7.45E−07 1.02E−06 8.29E−04 1.63E−09 1.45E−06 6.46E−07 2.88E−07 9.11E−10 3.42E−07 2.34E−07 4.39E−08 1.08E−10
  1. *Contributions from the 1% decay of 227Ac to 223Fr and daughters with a yield of less than 10–4% are not included